Increasing PV search efficiency and accuracy translates to better drug safety and patient outcomes. Conscious of the workload and compliance challenges involved in the crucial detection of drug safety signals, Elsevier continually develops solutions to help. With our R&D Solutions for PV, you can centralize information management and reporting, easily access key data sources, and automate adverse event detection.
Leverage our dedicated R&D Solutions for PV to:
See our exclusive webinar focusing on our 2018 enhancements to Embase, PharmaPendium and QUOSA PV. Discover what’s changed and how it improves the monitoring of relevant databases, assessment of captured information, and supervision of the workflow.
Thousands of pharmacovigilance and drug safety teams at pharmaceutical companies rely on Elsevier’s R&D Solutions and services. We have focused on providing comprehensive coverage of drug safety data sources and alleviating challenges with pharmacovigilance processes.
Promote efficiency and organizational compliance. QUOSA centralizes the discovery of adverse event information from multiple sources and automates information monitoring and triage in a scalable, GxP-compliant environment.
Make more informed decisions on drug safety and efficacy, risk, and study design. PharmaPendium delivers comparative drug interaction data and facilitates searches of FDA and EMA drug approval document sources, including FAERS.
Improve monitoring of biomedical literature for adverse events. Embase is the world’s most comprehensive database of peer-reviewed and grey biomedical literature. It includes crucial non-English content and offers unique support for search design.
Let informatics and analytics experts support your drug safety goals. Our Professional Services team can streamline adverse event and safety signal detection by validating search strategies and implementing solutions for literature triage and review.
A strong drug safety strategy with efficient risk–benefit analysis is a commitment to patient safety and a healthy drug life cycle. This new white paper assesses the five steps to follow in building an efficient, accurate and compliant strategy for capturing and reviewing adverse event information from the biomedical literature.
This new application note gives a step-by-step example of building a search for adverse drug events using Embase’s PV Wizard. The method described can be applied to any pharmacovigilance-focused search of the biomedical literature.
See how our workflow management tool promotes efficient and compliant pharmacovigilance. QUOSA helps you automate monitoring of relevant databases, streamline assessment of captured information, and more easily supervise the workflow.
Download the fact sheet (PDF, 359.2 KB)
Compliance is critical in the highly regulated world of pharmacovigilance. Find out how Elsevier’s Professional Services team helped one pharmaceutical company improve the compliance of their literature screening.
The FDA and EMA expect 100% of adverse drug reactions to be found in the literature monitoring process, so your search formula must be designed to achieve perfect recall. At the same time, though, you want to minimize the number of irrelevant records retrieved in order to maintain efficiency.
Read the white paper
Literature monitoring can help you report adverse events fast only if your process is up-to-date. With more data today than ever before — and more adverse events reported — monitoring has become more challenging. But the right solutions can help you.
Elsevier.com visitor survey
We are always looking for ways to improve customer experience on Elsevier.com.
We would like to ask you for a moment of your time to fill in a short questionnaire, at the end of your visit.
If you decide to participate, a new browser tab will open so you can complete the survey after you have completed your visit to this website.
Thanks in advance for your time.